Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19 | Zendy

David Seftel | Zendy; David R. Boulware | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19

Author(s) -

David Seftel,

David R. Boulware

Publication year - 2021

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofab050

Subject(s) - medicine , prospective cohort study , coronavirus , covid-19 , cohort , disease , infectious disease (medical specialty)

We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research